Rheumatology International

, Volume 32, Issue 9, pp 2837–2842 | Cite as

Registry of the clinical characteristics of spondyloarthritis in a cohort of Egyptian population

  • M. Y. Tayel
  • E. Soliman
  • W. F. El Baz
  • A. El Labaan
  • Y. Hamaad
  • M. H. Ahmed
Original Article


The aim of this study was to characterize the socioeconomic features, as well as disease activity and functional status, treatment use, and quality of life in a cohort of Egyptian population. All are measured by standard instruments. This is a descriptive multicenter; cross-sectional study included consecutive patients with spondyloarthritis (SpAs) diagnosed according to the European spondyloarthritis study group criteria. Four Egyptian centers participated (one from the Upper Egypt, one from the Delta, and two from the West Coast), all adopted the same criteria for patient assessment, and data were collected in the same data base over a 12-month duration. A total of 75 patients were included in the study. The series consisted of 34 ankylosing spondylitis (AS) patients (64%), 23 patients with psoriatic arthritis (45.3%), 15 patients with Juvenile onset AS (18.7%), 2 patients with reactive arthritis (2.7%), and one with inflammatory bowel disease–related arthritis (1.3%). There was predominance of male patients (84%). All were Caucasians; 13% from the Upper Egypt, and 87% from the Delta and West coast Egypt. Their mean age was 37.44 ± 12.8 years; mean disease duration was 11.85 ± 9.27 years. Pure axial disease was reported by 24% of the patients, and pure peripheral involvement was observed in 4%, while the mixed pattern (axial, peripheral, and entheseal) was observed in 34%. Dactylitis was detected in 9.3%, tarsitis in 8%, and enthesitis in 29.3%. The most common extra-articular manifestation was anterior uveitis, reported by 5.3% of patients. Human leukocytic antigen B27 (HLA-B27) was positive in 58.7% of the tested patients (n = 29). Mean Bath Ankylosing Spondylitis Disease activity Index (BASDAI) score was 4.16 ± 2.12, of which 22 patients had a score more than 4; mean Bath Ankylosing Spondylitis Functional Index 5.12 ± 2.40, mean BASMI 4.17 ± 2.95, mean BAS-GI 5.92 ± 2.00, and mean Health assessment questionnaire 1.10 ± 0.65. In addition, patients with AS showed a higher incapacity for work, felt more pain and presented more axial affection than others. The most utilized treatments were the conventional drugs including non-steroidal anti-inflammatory drugs, followed by sulfasalazine (50%), methotrexate (14%), and steroids (6%). Tumor necrosis factor-alpha inhibitors were received by 7 patients (14%), mostly in the form of Infliximab (85.7%) and were used by only 38.7% of patients with BASDAI of 4 or more. This registry provides the first clinical and demographic data of SpA patients in Egypt upon which a large-scale database registration can be initiated. The most frequently diagnosed SpA in Egyptian patients was AS, with mainly combined axial and peripheral involvement. The clinical spectrum of SpAs seen among Egyptians is similar to most other registries; however, Egyptian AS patients showed some differences in the clinical manifestations. The low frequency of HLA-B27 and the clinical variations in AS may be due to different genetic and/or environmental factors in Egypt.


Spondyloarthropathies Ankylosing spondylitis HLA-B27 Disease registry Egypt 


  1. 1.
    Khan MA (2002) Update on spondyloarthropathies. Ann Intern Med 135:896–907Google Scholar
  2. 2.
    Feldtkellel E, Lemmel EM, Russell AS (2003) Ankylosing spondylitis in the pharaohs of ancient Egypt. Rheumatol Int 23(1):1–5Google Scholar
  3. 3.
    Alvarez I, Lopez De Gastro JA (2000) HLA B27 and immunogenetics of spondyloarthropathies. Curr Opin Rheumatol 12:248–253PubMedCrossRefGoogle Scholar
  4. 4.
    Amor B, Dougados M, Listrat V et al (1991) Evaluation of the Amor criteria for spondyloarthropathies and the European spondyloarthropathy group study (ESSG). Ann Int Med 142:85–89Google Scholar
  5. 5.
    Jones SD, Steiner A, Calin A et al (1996) The Bath ankylosing spondylitis patient global score (BAS-G). Br J Rheumatol 35:66–71PubMedCrossRefGoogle Scholar
  6. 6.
    Garrett S, Jenkinson T, Kennedy LG et al (1994) BASDAI a new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21:2286–2291PubMedGoogle Scholar
  7. 7.
    Calin A, Garrett S, Whitelock H et al (1994) A new approach to defining functional ability in Ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21:2281–2285PubMedGoogle Scholar
  8. 8.
    Jenkinson T, Mallorie P, Whitelock H et al (1994) Defining spinal mobility in ankylosing spondylitis (AS). The bath AS metrology index. J Rheumatol 21:1694–1698PubMedGoogle Scholar
  9. 9.
    Uhrin Z, Kuzis S, Ward MM (2000) Exercise and changes in health status in patients with ankylosing spondylitis. Arch Intern Med 160(10):2969–2975PubMedCrossRefGoogle Scholar
  10. 10.
    Alvarez I, Lopez de Gastro JA (2000) HLA–B27 and immunogenetics of spondyloarhopathies. Curr Opin Rheumatol 12:248–253PubMedCrossRefGoogle Scholar
  11. 11.
    Sims AM, Timms AE, Bruges-Armas J, Bruges-Vargas R, Chou CT, Doan T et al (2008) Prospective meta-analysis of interleukin A gene complex polymorphism confirms associations with ankylosing spondylitis. Ann Rheum Dis 67:1305–1309PubMedCrossRefGoogle Scholar
  12. 12.
    Donna AF, Ismail AM, Moustafa F-H (2008) HLA class I typing in Egyptian childhood minimal change nephrotic syndrome. J Nephrol 21(5):734–737Google Scholar
  13. 13.
    Reveille JD (2011) The genetic basis of spondyloarthritis. Ann Rheum Dis 70(suppl 1):i44–i50PubMedCrossRefGoogle Scholar
  14. 14.
    Ferri S, Conighi C, Buzzanca G, Albertazzi R, Mattiuz PL (1982) Occurrence of HLA B27 antigen in ankylosing spondylitis in Italy. Revue du Rhumatisme et des Maladies Osteoarticulaires 49(5):355–358Google Scholar
  15. 15.
    Gunal E, Sarvan F, Kamali S, Gul A, Inanc M, Carin M, Konice M, Aral O, Ocal L (2009) Low frequency of HLA-B27 in ankylosing spondylitis patients from Turkey. Joint Bone Spine 75(3):299–302CrossRefGoogle Scholar
  16. 16.
    Fernández-Sueiro JL, Alonso C, Blanco FJ, Rodríguez-Gómez M, Galdo F, González-Gay MA (2004) Prevalence of HLA-B27 and subtypes of HLA-B27 associated with ankylosing spondylitis in Galicia, Spain. Clin Exper Rheumatol 22(4):465–468Google Scholar
  17. 17.
    Mijiyawa M, Oniankitan O, Khan MA (2000) Spondyloarthropathies in sub-Saharan Africa. Curr Opin Rheumatol 12(4):281–286PubMedCrossRefGoogle Scholar
  18. 18.
    Sakly N, Boumiza R, Zrour-Hassen S, Hamzaoui A, Ben Yahia S, Amara H, Khairallah M, Mahjoub S, Bergaoui N, Ghedira I (2009) HLA-B27 and HLA-B51 determination in Tunisian healthy subjects and patients with suspected ankylosing spondylitis and Behçet’s disease. Ann N Y Acad Sci 1173:564–569PubMedCrossRefGoogle Scholar
  19. 19.
    Al Attia HM, Sherif AM, Hossein M, Ahmed YH (2007) The demographic and clinical spectrum of Arab versus Asian patients with AS in UAE. Rheumatol Int 17(5):193–196CrossRefGoogle Scholar
  20. 20.
    Akkoc N, Khan MA (2006) Epidemiology of ankylosing spondylitis and related spondyloarthropathies. In: Weisman MH, van der Heidje D, Reveille JD (eds) Ankylosing spondylitis and spondyloarthropathies. Mosby, Philadelphia, pp 117–131Google Scholar
  21. 21.
    Collantes E, Zarco P, Munoz E, Jaunola X, Mulero J, Fernández-Sueiro JL et al (2007) Disease pattern of spondyloarthropathies in Spain: description of the first national registry (REGISPONSER). Rheumatology 46:1309–1315PubMedCrossRefGoogle Scholar
  22. 22.
    Bellomio V, Berman A, Sueldo R, Molina MJ, Spindler A, Lucero E et al (2008) Registro iberoamericano de espondiloartritis (RESPONDIA): Argentina. Rheumatol Clin 4(suppl 4):S23–S29Google Scholar
  23. 23.
    Saraux A, Guillemin F, Guggesbuhl P, Roux CH, Frardellone P, Le Bihan E et al (2005) Prevalence of spondyloarthropathies in France. Ann Rheum Dis 64:1431–1435PubMedCrossRefGoogle Scholar
  24. 24.
    Sampi-Barros PD, Bertolo MB, Kraemer MH, Marques-Neto JF, Samara AM (2001) Undifferentiated spondyloarthropathy; a two year follow up clinical study. Clin Rheumatol 20:201–206CrossRefGoogle Scholar
  25. 25.
    Zeider H, Mau W, Khan MA (1992) Undifferentiated spondyloarthropathies. Rheum Dis Clin North Am 18:187–202Google Scholar
  26. 26.
    Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A et al (1991) The European spondyloarthropathy study group. Preliminary criteria for the classification of spondyloarthropathy. Arthr Rheum 34:1218–1227CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • M. Y. Tayel
    • 1
  • E. Soliman
    • 1
  • W. F. El Baz
    • 2
  • A. El Labaan
    • 3
  • Y. Hamaad
    • 4
  • M. H. Ahmed
    • 5
  1. 1.Internal Medicine Department, Rheumatology Unit, Faculty of MedicineAlexandria UniversityAlexandriaEgypt
  2. 2.Internal Medicine Department, Rheumatology Unit, Faculty of MedicineEl Azhar UniversityCairoEgypt
  3. 3.Internal Medicine Department, Rheumatology Unit, Faculty of MedicineMenia UniversityEl-MeniaEgypt
  4. 4.Physical Medicine and Rehabilitation, Faculty of MedicineAlexandria UniversityAlexandriaEgypt
  5. 5.Biostatistics, High Institute of Public HealthAlexandria UniversityAlexandriaEgypt

Personalised recommendations